AI assistant
Summit Therapeutics Inc. — Director's Dealing 2025
Apr 9, 2025
30436_dirs_2025-04-09_fafaddf8-af5f-4efc-b3a8-72b8812031b6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2025-04-08
Reporting Person: Zanganeh Mahkam (Director, Co-Chief Executive Officer, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-04-08 | Common Stock | X | 3985055 | $1.58 | Acquired | 555680151 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-04-08 | Warrant (right to buy) | $1.58 | X | 3985055 | Acquired | 2029-12-24 | Common Stock (3985055) | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 10199776 | Indirect |
| Common Stock | 25457666 | Indirect |
| Common Stock | 50000 | Indirect |
| Common Stock | 31000 | Direct |
Footnotes
F1: On April 8, 2025, the Reporting Person's spouse exercised warrants to purchase an aggregate of 3,985,055 shares of the Issuer's common stock at an exercise price of $1.58 per share
F2: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.